Abstract
Neonatal hypoxic-ischemic encephalopathy continues to be a significant cause of death or neurodevelopmental delays despite standard use of therapeutic hypothermia. The use of stem cell transplantation has recently emerged as a promising supplemental therapy to further improve the outcomes of infants with hypoxic-ischemic encephalopathy. After the injury, the brain releases several chemical mediators, many of which communicate directly with stem cells to encourage mobilization, migration, cell adhesion and differentiation. This manuscript reviews the biomarkers that are released from the injured brain and their interactions with stem cells, providing insight regarding how their upregulation could improve stem cell therapy by maximizing cell delivery to the injured tissue.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1125-1135 |
| Number of pages | 11 |
| Journal | Neural Regeneration Research |
| Volume | 13 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2018 |
Keywords
- Brain-Derived neurotrophic
- Erythropoietin
- Factor
- Hypoxia inducible
- Matrix metalloproteinase
- Neonatal
- Stromal cell-derived
- Vascular endothelial growth
ASJC Scopus subject areas
- Developmental Neuroscience